Close Menu
    Latest Posts

    Pfizer Lyme disease vaccine fails trial, company to seek FDA approval

    March 23, 2026

    Paraguay signals neutral stance with pause in easing cycle

    March 23, 2026

    Gold enters bear market as Bitcoin ETFs attract record inflows

    March 23, 2026
    Facebook X (Twitter) Instagram
    Trending
    • Pfizer Lyme disease vaccine fails trial, company to seek FDA approval
    • Paraguay signals neutral stance with pause in easing cycle
    • Gold enters bear market as Bitcoin ETFs attract record inflows
    • Amazon’s Prime Day Shift: Why Moving It to June Matters
    • CLARITY Act Update: Crypto and Bank Reps Head to Capitol Hill to Review Stablecoin Deal as Details Remain Under Wraps
    • US, TotalEnergies to shift nearly $1 billion from wind to oil and gas
    • Rivian’s Making a Big Pivot, and the Results Could Be Huge
    • Fed's Miran Says Policy Can't Be Made on Short-Term Headlines
    Facebook X (Twitter) Instagram
    MoneyLister – Smart Investing & Financial NewsMoneyLister – Smart Investing & Financial News
    Tuesday, March 24
    • Home
    • Banking
    • Business
    • Crypto
    • Economy
    • Fintech
    • Investing
    • Markets
    • Stocks
    MoneyLister – Smart Investing & Financial NewsMoneyLister – Smart Investing & Financial News
    Home»Business»Dimon says Trump debanking lawsuit ‘has no merit’ but he’s sympathetic to concerns
    Business

    Dimon says Trump debanking lawsuit ‘has no merit’ but he’s sympathetic to concerns

    AdminBy AdminMarch 2, 2026No Comments2 Mins Read
    Share Facebook Twitter Pinterest Copy Link LinkedIn Tumblr Email VKontakte Telegram
    Dimon says Trump debanking lawsuit ‘has no merit’ but he’s sympathetic to concerns
    Share
    Facebook Twitter Pinterest Email Copy Link

    President Donald Trump (L), and JP Morgan CEO, Jamie Dimon.

    Reuters

    JPMorgan Chase CEO Jamie Dimon said Monday that while President Donald Trump’s lawsuit seeking $5 billion in damages for shuttering his accounts was without merit, he sympathized with the president’s anger over the episode.

    Trump is accusing JPMorgan and others of closing his accounts for political reasons in what his conservative supporters have called discrimination.

    “The case has no merit,” Dimon told CNBC’s Leslie Picker in an interview on the sidelines of a JPMorgan conference in Miami.

    “But I agree with them,” he said. “They have the right to be angry. I’d be angry, too. Like, why is a bank allowed to do that?”

    The answer, according to Dimon, is that banks are “forced” to debank individuals to comply with regulators who could punish companies for bringing reputational risk to a lender.

    “We debank people because it causes legal, regulatory risk for us,” Dimon said. “It’s been much easier for a bank to say, ‘I’m not taking the risk, let them go bank elsewhere.'”

    Trump sued Dimon and JPMorgan in January as part of a broader campaign begun after Trump regained office last year. The president, or his companies, has also sued Capital One over debanking claims; media outlets over alleged defamation; and even the IRS over the leak of his tax information.

    In recent court filings, JPMorgan acknowledged it closed dozens of accounts associated with Trump in the weeks after the Jan. 6, 2021, Capitol attack.

    While there isn’t an individual law stating that banks must drop customers over reputational risk, the industry operates under a framework of regulations and guidance that makes it risky for lenders to cater to certain clients.

    The suit against JPMorgan, the world’s biggest bank by market cap, and its CEO puts Dimon in an awkward position.

    It forces Dimon, one of the most outspoken leaders in finance, to toe the line between defending himself and his bank while not further angering Trump, who has the power to move markets with a social media post.

    Further, the financial industry is just starting to benefit from a deregulatory push by Trump appointees that will enable banks to become more profitable and hold less capital for losses.

    “There are a lot of misunderstandings here,” Dimon said. “Hopefully the law will change, and hopefully it’ll get sorted out.”

    Concerns debanking Dimon hes Lawsuit merit sympathetic Trump
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Telegram Copy Link
    Admin
    • Website

    Related Posts

    Business

    Pfizer Lyme disease vaccine fails trial, company to seek FDA approval

    March 23, 2026
    Business

    TSA lines surge at airports as government shutdown leaves officers unpaid

    March 22, 2026
    Business

    Robert Mueller, special counsel who probed but did not charge Trump, dies at 81

    March 21, 2026
    Markets

    Trump: We are very close to meeting our objectives in Iran

    March 21, 2026
    Business

    The Effects of High Oil Prices

    March 20, 2026
    Business

    Polk County recorder to retire

    March 19, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    Pfizer Lyme disease vaccine fails trial, company to seek FDA approval

    March 23, 2026

    Paraguay signals neutral stance with pause in easing cycle

    March 23, 2026

    Gold enters bear market as Bitcoin ETFs attract record inflows

    March 23, 2026

    Amazon’s Prime Day Shift: Why Moving It to June Matters

    March 23, 2026
    Latest Posts

    Subscribe to News

    Get the latest sports news from NewsSite about world, sports and politics.

    About Us

    Welcome to MoneyLister.com — your trusted source for reliable insights in the world of finance, investing, and digital assets.

    At MoneyLister, our mission is simple: to make complex financial topics easy to understand and accessible to everyone. Whether you're a beginner exploring cryptocurrency, an investor tracking the stock market, or a professional staying updated on global business trends, we provide clear, informative, and up-to-date content to help you stay ahead.

    Facebook X (Twitter) Instagram Pinterest YouTube
    Latest Posts

    Pfizer Lyme disease vaccine fails trial, company to seek FDA approval

    March 23, 2026

    Paraguay signals neutral stance with pause in easing cycle

    March 23, 2026

    Gold enters bear market as Bitcoin ETFs attract record inflows

    March 23, 2026
    Recent Posts
    • Pfizer Lyme disease vaccine fails trial, company to seek FDA approval
    • Paraguay signals neutral stance with pause in easing cycle
    • Gold enters bear market as Bitcoin ETFs attract record inflows
    • Amazon’s Prime Day Shift: Why Moving It to June Matters
    • CLARITY Act Update: Crypto and Bank Reps Head to Capitol Hill to Review Stablecoin Deal as Details Remain Under Wraps
    © 2026 moneylister. Designed by Pro.
    • About Us
    • Contact Us
    • Privacy Policy
    • Terms and Conditions
    • Disclaimer

    Type above and press Enter to search. Press Esc to cancel.